Dr. David Hermann, deputy director, is responsible for overseeing the TB Drugs portfolio and regimen development from discovery through product approval.
Prior to joining the foundation in 2017, David was engaged in drug development and advancing processes to facilitate data-driven decisions for over 25 years. His experiences with Glaxo, Pfizer, and deCODE genetics included designing and executing integrated clinical development plans as a member of global, multi-disciplinary development teams. Throughout he has been a champion of model-informed drug development, advocating the application of pharmacometric technologies to drug development decisions including in silico clinical trial simulation. In 2008, he co-founded the strategic drug development consultancy firm, Great Lakes Drug Development which was acquired by Certara in 2013. From 2012 to the present his responsibilities included managing a group of drug development consultants retained by the Integrated Development Team at the Bill & Melinda Gates Foundation. As a consultant to the foundation, he had the unique opportunity to support the TB program strategy and TB drug initiative teams providing input on drug stage-gate reviews, TB drug development strategy, and grant reviews. Further, he has witnessed the recent and dramatic expansion of the TB drug portfolio. With the influx of new compounds there is an unprecedented opportunity to shape future TB regimen development and David welcomes the opportunity to be part of this future.
David was a fellow in Clinical Research & Drug Development at University of North Carolina Chapel Hill from 1988-1990 and received his PharmD in Clinical Pharmacy at University of Illinois in 1988.
More about the foundation
Learn about the origins of the foundation and the values that drive our work.
Learn about where we work around the globe and the programs we've created to address urgent issues in global health, global development, and education.
Read the latest stories, research, and news from across the foundation and subscribe to our weekly newsletter, The Optimist.